Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine

BACKGROUND: A clinical ability to describe the response trajectory of patients receiving preventive migraine treatment could expedite and improve therapeutic management decisions. This post hoc analysis of the PROMISE-2 study evaluated the consistency and predictive power of Month 1 treatment respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Buse, Dawn C., Winner, Paul K., Charleston, Larry, Hirman, Joe, Cady, Roger, Brevig, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903499/
https://www.ncbi.nlm.nih.gov/pubmed/35189811
http://dx.doi.org/10.1186/s10194-022-01387-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903499/
https://www.ncbi.nlm.nih.gov/pubmed/35189811
http://dx.doi.org/10.1186/s10194-022-01387-y

Ejemplares similares